Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)

NCT03099161 | Terminated Phase 1 Results FDA Drug

• 2 other identifiers: 3814A-062MK-3814A-062
• Study Type: interventional
• Target: 10
• Locations: 3 countries
• Sites: 5

Brief Summary

The purpose of this study is to evaluate the safety and preliminary efficacy of preladenant (MK-3814A) alone and in combination with pembrolizumab (MK-3475) (pembro) in participants with advanced solid tumors that have not responded to prior therapy. This study will be done in 2 parts. Part 1 will identify and confirm the recommended Phase 2 dose (RP2D) of preladenant when given alone or in combination with pembrolizumab. Part 2 of the study will determine the safety and efficacy of preladenant in combination with pembrolizumab at the RP2D in participants with select solid tumors .

Conditions

Neoplasm

Keywords

Advanced Solid Tumor; Programmed Cell Death Receptor 1 (PD-1); Programmed Cell Death Receptor Ligand 1 (PD-L1); PD1; PD-1; PDL1; PD-L1

Outcome Measures

Primary Outcomes (3)

• Number of Participants With Dose-limiting Toxicities (DLTs)

  DLTs were assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4. A DLT was defined as any of the following events: Grade (Gr) 4 non-hematologic toxicity (not laboratory); Gr 4 hematologic toxicity lasting ≥7 days; Gr 4 thrombocytopenia of any duration; Gr 3 thrombocytopenia with bleeding; Gr 3 non-hematologic toxicity (not laboratory) lasting \>3 days despite optimal supportive care; Gr 3 or Gr 4 non-hematologic laboratory value requiring treatment, hospitalization, or persisting for \>72 hours; alanine aminotransferase (ALT) or aspartate aminotransferase(AST) \>3X upper limit of normal (ULN) WITH total bilirubin \>2X ULN with no elevation in alkaline phosphatase (\<2X ULN); Febrile neutropenia Gr 3 or 4; discontinuation during Cycle 1 or a \>2 week delay in initiating Cycle 2 due to treatment-related toxicity; Missing \>25% of preladenant doses as a result of adverse events during Cycle 1; or Gr 5 toxicity.

  Cycle 1 (up to 21 days)

• Number of Participants Who Experienced at Least One Adverse Event (AE)

  An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product/protocol-specified procedure, whether or not considered related to the medicinal product/protocol-specified procedure. Any worsening of a preexisting condition temporally associated with the use of the product was also an AE. The number of participants who experienced at least one AE is presented.

  Up tp approximately 8 months

• Number of Participants Who Discontinued Study Treatment Due to an AE

  An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product/protocol-specified procedure, whether or not considered related to the medicinal product/protocol-specified procedure. Any worsening of a preexisting condition temporally associated with the use of the product was also an AE. The number of participants who discontinued study treatment due to an AE is presented.

  Up to approximately 8 months

Secondary Outcomes (1)

• Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

  Up to approximately 8 months

Study Arms (3)

Preladenant 25 mg Twice a Day (BID)

EXPERIMENTAL

During an initial dose evaluation phase, participants received 25 mg of preladenant orally twice a day (BID) on Days 1 through 21 of each 21-day cycle (for a maximum of 35 cycles) until the RP2D could be established. The RP2D was to be established based on the number of dose limiting toxicities (DLTs) at each dose level administered. Participants continued receiving 25 mg of preladenant BID on Days 1 through 21 of each infusion cycle until discontinuation or receiving a maximum of 35 cycles.

Drug: preladenant

Preladenant 50 mg BID

EXPERIMENTAL

During an initial dose evaluation phase, participants received 50 mg of preladenant orally BID on Days 1 through 21 of each 21-day cycle (for a maximum of 35 cycles) until the RP2D could be established. The RP2D was established based on the number of DLTs at each dose level administered. Participants continued receiving 50 mg of preladenant BID on Days 1 through 21 of each infusion cycle until discontinuation or receiving a maximum of 35 cycles.

Drug: preladenant

Preladenant + Pembrolizumab

EXPERIMENTAL

During an initial dose evaluation phase, participants received 25 mg of preladenant administered orally BID on Days 1 through 21 in combination with 200 mg pembrolizumab administered as an intravenous (IV) infusion on Day 1 of each 21-day cycle (for a maximum of 35 cycles). Participants continued receiving preladenant 25 mg BID in combination with 200 mg pembrolizumab for each infusion cycle until discontinuation or receiving a maximum of 35 cycles.

Drug: preladenant; Biological: pembrolizumab

Interventions

preladenant DRUG

Administered as an oral capsule BID on Days 1 through 21 of each 21-day cycle

Also known as: MK-3814A

Preladenant + Pembrolizumab; Preladenant 25 mg Twice a Day (BID); Preladenant 50 mg BID

pembrolizumab BIOLOGICAL

Administered as IV infusion on Day 1 of each 21-day cycle

Also known as: KEYTRUDA®, MK-3475

Preladenant + Pembrolizumab

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Has a histologically- or pathologically-documented, locally-advanced or metastatic solid tumor for which standard therapy, either does not exist or has been proven ineffective, intolerable or refused by the participant. Each participant must have received at least one and up to five prior lines of cancer treatment regimens, excluding neo-adjuvant, adjuvant, maintenance treatment and surgery
• Has provided a tumor tissue sample (archival or newly obtained core or excisional biopsy of a tumor lesion)
• Has measurable disease per RECIST 1.1
• Has an Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• Females must not be pregnant
• Female and male participants of reproductive potential must agree to use adequate contraception starting from the first dose of study therapy, throughout the study period, and for up to 120 days after the last dose of study therapy

You may not qualify if:

• Has disease that is suitable for local treatment administered with curative intent
• Has received previous treatment with an immunomodulatory agent (e.g, anti- Programmed Cell Death Receptor 1/ Programmed Cell Death Receptor Ligand 1 or anti-cytotoxic T-lymphocyte-associated antigen-4) and was discontinued from treatment due to a Grade 3 or higher immune-related adverse event
• Has received previous treatment with an adenosine A2a receptor antagonist (e.g. CPI-444, HTL1071, PBF-509)
• Has had chemotherapy, definitive radiation, or biological cancer therapy within 4 weeks of the first dose of study therapy, or has not recovered to Common Toxicity Criteria for Adverse Events (CTCAE) grade 1 or better from any adverse event
• Is currently participating or has participated in a study with an investigational agent or using an investigational device within 28 days of the first dose of study therapy
• Is currently taking or has taken drugs that interfere with Cytochrome P450 (CYP)3A4 or CYP2C8 or grapefruit and star fruit in diet within 14 days of the first dose of study therapy
• Is currently taking or has taken proton pump inhibitors within 5 days of the first dose of study therapy
• Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days of the first dose of study therapy
• Is expected to require any other form of systemic or localized antineoplastic therapy while on study
• Has a history of a second malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for 5 years
• Has clinically active central nervous system metastases and/or carcinomatous meningitis
• History of a severe hypersensitivity reaction to treatment with the monoclonal antibody/components of the study drug
• Has an active infection requiring therapy
• History of interstitial lung disease
• History of (non-infectious) pneumonitis that required steroids or current pneumonitis

Sponsors & Collaborators

• Merck Sharp & Dohme LLC: lead

Study Sites (5)

START Midwest ( Site 0001)

Grand Rapids, Michigan, 49546, United States

Location

Princess Margaret Hospital ( Site 0010)

Toronto, Ontario, H9H 4M7, Canada

Location

Jewish General Hospital ( Site 0011)

Montreal, Quebec, H9H 4M7, Canada

Location

Rambam Health Care Campus ( Site 0020)

Haifa, Israel

Location

Tel Aviv Sourasky Medical Center ( Site 0021)

Tel Aviv, Israel

Location

MeSH Terms

Conditions

Neoplasms; Parkinson Disease 4, Autosomal Dominant Lewy Body

Interventions

2-(2-furanyl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)-1-piperazinyl)ethyl)-7H-pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidine-5-amine; pembrolizumab

Limitations and Caveats

This study was terminated early because the data did not support the study endpoints.

Results Point of Contact

• Title: Senior Vice President, Global Clinical Development
• Organization: Merck Sharp & Dohme Corp.

ClinicalTrialsDisclosure@merck.com

1-800-672-6372

Study Officials

• Medical Director

  Merck Sharp & Dohme LLC

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 30, 2017
• First Posted: April 4, 2017
• Study Start: June 27, 2017
• Primary Completion: November 24, 2017
• Study Completion: February 21, 2018
• Last Updated: June 5, 2019
• Results First Posted: June 5, 2019

Record last verified: 2019-02

Data Sharing

• IPD Sharing: Will share

Locations

CA (2); IL (2); US (1)